

Potential Disease-Modifying Therapies in the Parkinson's Disease Clinical Trial Pipeline

last update: Nov. 28, 2018

Goal: Enable PD community to more easily **identify recruiting, planning and funding needs** for high-priority research towards a cure.

Compiled by Sue Buff & Gary Rafaloff

Source: ClinicalTrials.gov, The Cure Parkinson's Trust - LCT Programme (CPT-LCT), Michael J. Fox Foundation (MJFF), industry websites, researchers & advocates (Simon Stott: ScienceofParkinsons.com, Kevin McFarthing: The Hope List-Parkinson's Therapies in Development)

Send feedback to: SueBuff@outlook.com

File available at PDTracker.info

Disease Modifying Therapies for PD: Select trials in the planning stage				
Therapy	Description	More Info		
EPI-743	Targeted at mitochondrial and other neuro diseases	CPT - LCT Program (Edison Pharma, Phase 2B)	Neurology.org April 2016 EPI-743 Phase 2A results	Phase 2A completed (NCT01923584)
UDCA*	Used to treat liver disease. Acts to recover mitochondrial function.	Trial pending per CPT - LCT Program	University of Sheffield, CPT-LCT inc. VARI Jon Moulton CT	More on UDCA at scienceofparkinsons.com
MSDC-0160* (Mitoglitazone)	Originally developed to treat Type 2 diabetes. May improve mitochondrial function in PD.	CPT - Linked Clinical Trials: VARI, CPT, Metabolic Solutions collaboration	Clinical trial in design	www.msdrx.com/pipeline/msdc-0160
NAC (n-Acetyl Cysteine)*	Treats acetaminophen overdose. Used to loosen mucous in cystic fibrosis & COPD.	Trial in design (CPT: NAC Trial-The Facts)	CPT - Linked Clinical Trials Program	NAC Phase 1 completed 2012 (NCT01427517)
Exenatide (Bydureon)*	Type 2 Diabetes drug (GLP-1 agonist)	Phase 2 EXENATIDE-PD study completed (NCT01971242). Sponsors: University College, London, CPT-LCT inc VARI. Timeframe: June 2014 - Aug. 2016. 60 enrolled.	Results of completed Phase 2 EXENATIDE-PD on CPT website & Lancet. (see also CPT-LCT Program: www.cureparkinsons.org.uk/trials-repurposed-drugs) (see also www.michaeljfox.org/foundation/grant-detail.php?grant_id=1124)	Journal of PD. 8.8.17, Exenatide Phase 2 study commentary
SR Exenatide (PT302)	Type 2 Diabetes drug (GLP-1 agonist)	Peptron (Korea) evaluating SR Exenatide (PT302) for PD: planning Phase 2		
NPT200-11 (UCB 1332)	Alpha-synuclein vaccine	NPT200 Phase 1B planned by UCB/Neuropore per MJFF update on alpha-syn trials 7/10/17	www.neuropore.com/programs/	Neuropore Announces Successful Completion of Phase I with NPT200-11, 3.22.16 (NCT02606682)
NPT088	Alpha-synuclein vaccine	Awaiting results from Alzheimer's phase 1B NCT03008161 (est. completion 4/19) per MJFF update on alpha-syn trials 7/10/17	Ref. MJFF NPT088 research grant	Proclara Biosciences - Our Programs (Phase 1B for Alzheimer's NCT03008161)
GM608	Neurotrophic factors	Phase 2B (or 3) planned	GM608 Phase 2A (GAP-PD: NCT01850381) completed in July 2014.	Genervon.com - Pipeline
SCC-138	Abl & Fin kinase inhibitor /potential alpha-syn affect	Sun Pharma (SPARC) planning Phase 2 of SCC-138 in Q3 2019 at multiple sites in N. America, Asia, Europe	Seekingalpha - SPARC slideshow Sept. 2018, ref. slides 19 - 22	

GDNF	Gene therapy	medgenesis.com - Feb. '18 press release; planning Phase 3	Medgenesis GDNF program received grants from MJFF, Parkinsons UK	Phase 2 Study "GDNF in Idiopathic PD" (NCT03652363) completed. Sponsor: North Bristol NHS Trust. Timeframe: Oct. 2012- Apr. 2016, with 42 enrolled.
AAV-GAD	parkinsonsnewstoday.com : 2018.12.03 Parkinsons gene therapy works creating new brain circuits)	Oct. 2018: Meiragtx announces acquisition of Vector Neurosciences (Note: Vector Neurosciences had previously acquired Neurologix assets. Neurologix sponsored Phase 2 NCT00643890)	Phase 2 NCT00643890 "Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease" was completed in 2010 (but status is "terminated on CT.gov)	publ. of Phase 2 results in The Lancet, 3.17.11